Sosei to Host Town Hall Meetings for Individual Shareholders in Nagoya and Osaka

Tokyo, Japan and London, UK, 24 May 2018 – Sosei Group Corporation ("Sosei" or the "Company"; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, today announced that the Company will hold two Town Hall Meetings to provide Sosei's individual shareholders and other interested parties the opportunity to meet with senior management. The Town Hall Meetings will take place on 25 June 2018 in the cities of Nagoya and Osaka.

Peter Bains, CEO, and Andrew Oakley, CFO, will present an update on the Company's pipeline and strategy, and will be available for a question and answer session with shareholders.

If you wish to attend one of the events, please apply by registering your details at one of the URL links below by no later than 15 June 2018. Please note, on the day of the event, we ask that you please bring your invitation voucher to present to reception at the venue. The participation voucher will be delivered via email following successful completion of your application.

The details and attendee registration link for each Town Hall Meeting is below.

- **Nagoya Town Hall Meeting**
  - Date: Monday 25 June 2018
  - Time: 10:00am–11:30am
  - Address: JR Gate Tower, 16th Floor, 1-1-3 Meieki, Nakamura-ku, Nagoya City
  - Map link: Please click here
  - Attendee registration link (Japanese only): Please click here
  - Other details: Please note this event is limited to 60 participants, and invitation vouchers will be allocated on a first-come-first-served basis

- **Osaka Town Hall Meeting**
  - Date: Monday 25 June 2018
  - Time: 3:30pm–5:00pm
  - Address: Hankyu Grand Building, 26th Floor, 8-47 Kakuda-cho, Kita-ku, Osaka City
  - Map link: Please click here
  - Attendee registration link (Japanese only): Please click here
  - Other details: Please note this event is limited to 100 participants, and invitation vouchers will be allocated on a first-come-first-served basis

-Ends-

Enquiries:

Sosei +44 (0) 7912 892 199
Chris Cargill, Head of Investor Relations and Corporate Communications
ccargill@sosei.com

Citigate Dewe Rogerson (for international media) +44 (0) 20 7638 9571
Mark Swallow
David Dible
sosei@citigatedewerogerson.com

About Sosei

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company's leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit http://www.sosei.com/en/.